title: [Methods of preventing phlebitis induced by infusion of fosaprepitant].
abstract: At our hospital, we use aprepitant for nausea and vomiting when administering highly emetic anticancer agents, according to "Guidelines for the Appropriate Use of Antiemetic Agents" given by the Japan Society of Clinical Oncology. We initiated the intravenous administration of fosaprepitant for better compliance compared with aprepitant; however, we observed phlebitis after the infusion of fosaprepitant. Therefore, we investigated measures to reduce phlebitis associated with the infusion of fosaprepitant. For the first premedication, fosaprepitant (150 mg) was dissolved in 100 mL of saline and administered for 30 minutes; 1 of 2 patients showed grade 4 phlebitis. For the modified premedication, fosaprepitant, dexamethasone, and 5- HT(3) antagonist were dissolved in 100 mL of saline and administered for 30 minutes. The modified premedication was administered to a total of 27 patients; 5 patients developed mild phlebitis (grade 1), but infusion could be continued by treating their phlebitis with a hot pack. We used a combination of dexamethasone and 5-HT(3) antagonist with fosaprepitant as a modified premedication in order to avoid drug-induced vascular damage, which resulted in the pH decreasing to 6.20-7.55 (close to neutral) and a shorter infusion time.
authors: Dept. of Pharmacy, Kansai Medical University, Kori Hospital.
authors: Emiko
authors: E
authors: Kohno
authors: Sayaka
authors: S
authors: Kanematsu
authors: Satoshi
authors: S
authors: Okazaki
authors: Makoto
authors: M
authors: Ogata
authors: Meiko
authors: M
authors: Kanemitsu
authors: Hiromi
authors: H
authors: Yamashita
authors: Kaori
authors: K
authors: Syuntou
authors: Masako
authors: M
authors: Sekita
authors: Ryoko
authors: R
authors: Nishioka
authors: Hideyuki
authors: H
authors: Yoshida
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D010689:Phlebitis / Q000139:chemically induced / Q000517:prevention & control*; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D009025:Morpholines; C579707:fosaprepitant